Catalyst Biosciences’ (CBIO) Buy Rating Reaffirmed at Chardan Capital
Chardan Capital reaffirmed their buy rating on shares of Catalyst Biosciences (NASDAQ:CBIO) in a research note issued to investors on Sunday morning, AnalystRatings.com reports. Chardan Capital currently has a $25.00 target price on the biopharmaceutical company’s stock.
CBIO has been the subject of several other reports. Zacks Investment Research cut shares of Catalyst Biosciences from a buy rating to a hold rating in a research report on Wednesday, October 2nd. ValuEngine raised shares of Catalyst Biosciences from a hold rating to a buy rating in a research report on Thursday, August 1st. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of $19.88.
Shares of NASDAQ:CBIO traded up $0.01 on Friday, hitting $5.28. The company had a trading volume of 100 shares, compared to its average volume of 95,494. The firm’s 50-day simple moving average is $5.48 and its two-hundred day simple moving average is $7.09. Catalyst Biosciences has a 1 year low of $4.52 and a 1 year high of $11.29. The company has a quick ratio of 9.82, a current ratio of 9.82 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $69.36 million, a price-to-earnings ratio of -1.97 and a beta of 2.18.
Several institutional investors have recently modified their holdings of CBIO. Essex Woodlands Management Inc. bought a new stake in Catalyst Biosciences during the 2nd quarter valued at about $579,000. GSA Capital Partners LLP purchased a new position in shares of Catalyst Biosciences during the 2nd quarter valued at approximately $299,000. Vanguard Group Inc. lifted its position in shares of Catalyst Biosciences by 6.0% during the 2nd quarter. Vanguard Group Inc. now owns 592,039 shares of the biopharmaceutical company’s stock valued at $4,363,000 after buying an additional 33,504 shares in the last quarter. Atria Investments LLC purchased a new position in shares of Catalyst Biosciences during the 2nd quarter valued at approximately $176,000. Finally, Morgan Stanley lifted its position in shares of Catalyst Biosciences by 3,533.8% during the 2nd quarter. Morgan Stanley now owns 242,013 shares of the biopharmaceutical company’s stock valued at $1,784,000 after buying an additional 235,353 shares in the last quarter. Institutional investors own 62.66% of the company’s stock.
About Catalyst Biosciences
Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.
Further Reading: Market Indexes
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.